121 related articles for article (PubMed ID: 12694247)
1. Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma.
Vincent T; Molina L; Espert L; Mechti N
Br J Haematol; 2003 Apr; 121(2):259-69. PubMed ID: 12694247
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein.
Vincent T; Jourdan M; Sy MS; Klein B; Mechti N
J Biol Chem; 2001 May; 276(18):14728-36. PubMed ID: 11278272
[TBL] [Abstract][Full Text] [Related]
3. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva I; Thomas X; Epstein J
Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
[TBL] [Abstract][Full Text] [Related]
4. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells.
Ohwada C; Nakaseko C; Koizumi M; Takeuchi M; Ozawa S; Naito M; Tanaka H; Oda K; Cho R; Nishimura M; Saito Y
Eur J Haematol; 2008 Mar; 80(3):245-50. PubMed ID: 18081709
[TBL] [Abstract][Full Text] [Related]
5. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
7. Extracellular matrix in bone marrow can mediate drug resistance in myeloma.
Vincent T; Mechti N
Leuk Lymphoma; 2005 Jun; 46(6):803-11. PubMed ID: 16019524
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
9. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.
Frassanito MA; Cusmai A; Iodice G; Dammacco F
Blood; 2001 Jan; 97(2):483-9. PubMed ID: 11154226
[TBL] [Abstract][Full Text] [Related]
10. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells.
Hönemann D; Chatterjee M; Savino R; Bommert K; Burger R; Gramatzki M; Dörken B; Bargou RC
Int J Cancer; 2001 Sep; 93(5):674-80. PubMed ID: 11477577
[TBL] [Abstract][Full Text] [Related]
11. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.
Zdzisińska B; Bojarska-Junak A; Dmoszyńska A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2008; 56(3):207-21. PubMed ID: 18512025
[TBL] [Abstract][Full Text] [Related]
12. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
Voorhees PM; Chen Q; Small GW; Kuhn DJ; Hunsucker SA; Nemeth JA; Orlowski RZ
Br J Haematol; 2009 May; 145(4):481-90. PubMed ID: 19344406
[TBL] [Abstract][Full Text] [Related]
13. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
Shiao RT; Miglietta L; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1995 May; 17(5-6):485-94. PubMed ID: 7549842
[TBL] [Abstract][Full Text] [Related]
17. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
Wu Y; Wang H
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
[TBL] [Abstract][Full Text] [Related]
18. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
19. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
20. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone.
Puthier D; Bataille R; Barillé S; Mellerin MP; Harousseau JL; Ponzio A; Robillard N; Wijdenes J; Amiot M
Blood; 1996 Dec; 88(12):4659-66. PubMed ID: 8977259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
